Skip to main content

Advertisement

Table 1 Characteristics of the RA patients

From: Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease

      ILD(+)RA UIP(+)RA NSIP(+)RA
ILD(+)RA UIP(+)RA NSIP(+)RA ILD(−)RA P P P
Number   32 18 14 32    
Age year 70.2 (7.4) 70.6 (8.0) 69.6 (6.8) 57.7 (13.8) 0.0002 0.0013 0.0043
male number n (%) 11 (34.4) 9 (50.0) 2 (14.3) 2 (6.3) *0.0109 *0.0007 *0.5745
Disease duration year 15.5 (12.6) 12.8 (12.2) 18.9 (12.7) 10.6 (7.4) 0.1830 0.8953 0.0116
Steinbrocker stage III and IV n (%) 18 (56.3) 9 (50.0) 9 (64.3) 21 (65.6) *0.6088 *0.3701 *1.0000
Smoker or past smoker n (%) 10 (33.3) 7 (38.9) 3 (25.0) 10 (32.3) *1.0000 *0.7581 *0.7272
Rheumatoid factor positive n (%) 30 (93.8) 17 (94.4) 13 (92.9) 27 (84.4) *0.4258 *0.3991 *0.6506
Anti-citrullinated peptide antibody positive n (%) 31 (96.9) 18 (100.0) 13 (92.9) 31 (96.9) *1.0000 *1.0000 *0.5208
KL-6 U/ml 1096.4 (853.7) 1086.2 (828.4) 1108.8 (914.9) 315.3 (257.9) 2.44 × 10−7 2.97 × 10−6 0.0001
SP-D ng/ml 194.1 (244.7) 177.3 (192.3) 214.5 (303.0) 46.0 (37.5) 2.48 × 10−5 0.0008 0.0001
DAS28   4.0 (1.2) 3.7 (1.3) 4.3 (0.9) 3.1 (1.2) 0.0040 0.0793 0.0021
DAS28-CRP   3.0 (1.3) 2.6 (1.4) 3.4 (1.0) 2.4 (1.0) 0.0500 0.5855 0.0035
NSAIDs administration n (%) 13 (41.9) 7 (38.9) 6 (46.2) 15 (48.4) *0.7989 *0.5647 *1.0000
Corticosteroid administration n (%) 26 (83.9) 14 (77.8) 12 (92.3) 25 (80.6) *1.0000 *1.0000 *0.6542
DMARDs administration n (%) 24 (77.4) 14 (77.8) 10 (76.9) 30 (96.8) *0.0529 *0.0542 *0.0706
sDMARDs administration n (%) 19 (61.3) 11 (61.1) 8 (61.5) 19 (61.3) *1.0000 *1.0000 *1.0000
bDMARDs administration n (%) 10 (32.3) 5 (27.8) 5 (38.5) 22 (71.0) *0.0048 *0.0066 *0.0874
  1. Average values or numbers of each group are shown. Standard deviations or percentages are shown in parenthesis. Differences were tested by Mann-Whitney’s U test or Fisher’s exact test using 2 × 2 contingency tables
  2. RA rheumatoid arthritis, ILD interstitial lung disease, UIP Usual interstitial pneumonia, NSIP Nonspecific interstitial pneumonia, ILD(+)RA RA with ILD, UIP(+)RA RA with ILD of UIP pattern, NSIP(+)RA RA with ILD of NSIP pattern, ILD(−)RA RA without ILD, KL-6 krebs von den lungen-6, SP-D Surfactant protein-D, DAS28 disease activity score 28, NSAIDs non-steroidal anti- inflammatory drug, DMARD disease-modifying anti-rheumatic drug, sDMARD synthetic DMARD, bDMARD biological DMARD
  3. *Fisher’s exact test was employed